Literature DB >> 25428636

Surgical aspects of decompression craniectomy in malignant stroke: review.

Klaus Zweckberger1, Eric Juettler, Julian Bösel, W Andreas Unterberg.   

Abstract

BACKGROUND: Space-occupying malignant stroke of the middle cerebral artery (MCA) is associated with a high mortality rate of up to 80% under conservative treatment. Although there is convincing evidence that decompression craniectomy can significantly reduce mortality rate and improve neurological outcome in young patients (<60 years), many surgeons are still hesitant to recommend hemicraniectomy for stroke patients.
SUMMARY: This review addresses some major issues that appear to be an obstacle to decompression craniectomy, in particular, indicating surgery for patients >60 years or with infarcts of the dominant hemisphere. Furthermore, it emphasizes technical issues such as timing and size of the craniectomy, additional temporal lobectomy, and resection of the temporal muscle, as well as duraplasty and cranioplasty. According to the current literature, decompression craniectomy in older patients can increase survival without most severe disabilities, although, most survivors need assistance in most bodily needs. Involvement of the dominant hemisphere results in aphasia that might partly recover in younger patients, although, considering the neuropsychological deficits caused by infarctions of the nondominant hemisphere, involvement of the dominant hemisphere does not pose as a contraindication for decompression craniectomy. Furthermore, there is convincing evidence that surgery should be performed within 48 h after the onset of symptoms and the size of the craniectomy should be at least 12 cm as a minimum. An additional lobectomy or the resection of the temporal muscle, however, can only be part of individual treatment options. Conceding the weak evidence, it is recommended to close the dura by some form of a duraplasty avoiding cerebrospinal fluid leakages or scarring between the cortex and the scalp leading to injuries during reimplantation of the bone-flap. Complications associated with decompression surgery (hemorrhages, infections, 'sinking skin-flap syndrome', cerebrospinal fluid leakages, hydrocephalus, seizures), with the infarction itself, or with those that occur during the ICU course (cardiac and pulmonary complications) appear acceptable and are mostly treatable, especially considering the fatal course of conservative treatment. Key Message: This review summarizes the current state of the literature about decompression craniectomy of patients with malignant stroke addressing, in particular, critical surgical issues, and thus, help surgeons to make decisions confidently for/or against performing surgery.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25428636     DOI: 10.1159/000365864

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  13 in total

1.  Study on the behavioral changes of a post-stroke depression rat model.

Authors:  Chunfang Wu; Junhe Zhang; Yong Chen
Journal:  Exp Ther Med       Date:  2015-04-24       Impact factor: 2.447

2.  [Intensive care therapy of space-occupying large hemispheric infarction. Summary of the NCS/DGNI guidelines].

Authors:  J Bösel; S Schönenberger; C Dohmen; E Jüttler; D Staykov; K Zweckberger; W Hacke; S Schwab; M T Torbey; H B Huttner
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

3.  Infarct volume predicts outcome after decompressive hemicraniectomy for malignant hemispheric stroke.

Authors:  Nils Hecht; Hermann Neugebauer; Ingo Fiss; Alexandra Pinczolits; Peter Vajkoczy; Eric Jüttler; Johannes Woitzik
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-30       Impact factor: 6.200

Review 4.  Today's Approach to Treating Brain Swelling in the Neuro Intensive Care Unit.

Authors:  Shreyansh Shah; W Taylor Kimberly
Journal:  Semin Neurol       Date:  2016-12-01       Impact factor: 3.420

5.  Patient Age and the Outcomes after Decompressive Hemicraniectomy for Stroke: A Nationwide Inpatient Sample Analysis.

Authors:  Hormuzdiyar H Dasenbrock; Faith C Robertson; M Ali Aziz-Sultan; Donovan Guittieres; Rose Du; Ian F Dunn; William B Gormley
Journal:  Neurocrit Care       Date:  2016-12       Impact factor: 3.210

6.  Radiological signs of the syndrome of the trephined.

Authors:  Lana Vasung; Marion Hamard; Maria Carmen Alcaraz Soto; Samuel Sommaruga; Lukas Sveikata; Beatrice Leemann; Maria Isabel Vargas
Journal:  Neuroradiology       Date:  2016-02-23       Impact factor: 2.804

7.  Intracranial Pressure as an Objective Biomarker of Decompression Adequacy in Large Territory Infarction: A Multicenter Observational Study.

Authors:  Jia Xu Lim; Sherry Jiani Liu; Tien Meng Cheong; Seyed Ehsan Saffari; Julian Xinguang Han; Min Wei Chen
Journal:  Front Surg       Date:  2022-05-06

8.  Epileptiform activity and spreading depolarization in the blood-brain barrier-disrupted peri-infarct hippocampus are associated with impaired GABAergic inhibition and synaptic plasticity.

Authors:  Kristina Lippmann; Lyn Kamintsky; Soo Young Kim; Svetlana Lublinsky; Ofer Prager; Julia Friederike Nichtweiss; Seda Salar; Daniela Kaufer; Uwe Heinemann; Alon Friedman
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

9.  Decompressive Hemicraniectomy in Elderly Patients With Space-Occupying Infarction (DECAP): A Prospective Observational Study.

Authors:  Jan Rahmig; Sigrid Wöpking; Eric Jüttler; Lorenz Uhlmann; Ronald Limprecht; Jessica Barlinn; Gabriele Schackert; Heinz Reichmann; Hauke Schneider
Journal:  Neurocrit Care       Date:  2019-08       Impact factor: 3.210

10.  German Cranial Reconstruction Registry (GCRR): protocol for a prospective, multicentre, open registry.

Authors:  Henrik Giese; Thomas Sauvigny; Oliver W Sakowitz; Michael Bierschneider; Erdem Güresir; Christian Henker; Julius Höhne; Dirk Lindner; Dorothee Mielke; Robert Pannewitz; Veit Rohde; Martin Scholz; Patrick Schuss; Jan Regelsberger
Journal:  BMJ Open       Date:  2015-09-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.